2018
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Rindi G, Klimstra D, Abedi-Ardekani B, L. S, Bosman F, Brambilla E, Busam K, de Krijger R, Dietel M, El-Naggar A, Fernandez-Cuesta L, Klöppel G, McCluggage W, Moch H, Ohgaki H, Rakha E, Reed N, Rous B, Sasano H, Scarpa A, Scoazec J, Travis W, Tallini G, Trouillas J, van Krieken J, Cree I. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology 2018, 31: 1770-1786. PMID: 30140036, PMCID: PMC6265262, DOI: 10.1038/s41379-018-0110-y.Peer-Reviewed Original ResearchConceptsNeuroendocrine neoplasmsNeuroendocrine tumorsInternational Agency for Research on CancerExpression of neuroendocrine markersKi-67 labeling indexClassification of neuroendocrine neoplasmsWorld Health OrganizationPresence of necrosisOrgan systemsPrognostic factorsCarcinoid tumorsPrognostic differencesNeuroendocrine markersKi-67Mitotic countTumor biologyLabeling indexAnatomical sitesOrgan-specific differencesAnatomical locationConsensus conferenceNeoplasmsTumorClassification criteriaCancer
2016
FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid
Kang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid. Scientific Reports 2016, 6: 34022. PMID: 27677402, PMCID: PMC5039724, DOI: 10.1038/srep34022.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerAtypical carcinoidLung cancerTypical carcinoidNE tumorsSCLC cellsTherapeutic targetNon-small cell lung cancerDiagnostic markerLung NE tumorsNE tumor markersWorse clinical outcomesLung neuroendocrine tumorsPresence of necrosisPotential therapeutic targetNew therapeutic targetsUseful diagnostic markerNumber of mitosesBetter diagnostic criteriaFas apoptosis pathwayNE cancersClinical outcomesNeuroendocrine tumorsFAIM2 expression18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, Kobayashi K, Watanabe S, Shiga T, Terasaka S, Kobayashi H, Kuge Y, Tamaki N. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 43: 1469-1476. PMID: 26841941, DOI: 10.1007/s00259-016-3320-x.Peer-Reviewed Original ResearchConceptsPresence of necrosisBrain tumorsFMISO PETFMISO uptakeSevere hypoxiaFMISO PET/Brain tumor patientsPositron emission tomography (PET) tracerPositron emission tomographyEmission tomography tracerHistopathological necrosisPathological necrosisPoor prognosisSurgical strategyIntratumoral necrosisNeuroepithelial tumorsTumor resectionPathological diagnosisTumor patientsCerebellum ratioTreatment decisionsMethodsThis studyGroup 2Group 1Experienced neuropathologist
2013
Does removal of DCIS decrease the incidence of invasive breast cancer?
Killelea B, Christy C, Horowitz N, Tsangaris T, Dixon M, Chagpar A, Grube B, Lannin D. Does removal of DCIS decrease the incidence of invasive breast cancer? Journal Of Clinical Oncology 2013, 31: 2-2. DOI: 10.1200/jco.2013.31.26_suppl.2.Peer-Reviewed Original ResearchHigh-grade DCISInvasive cancerDCIS componentSEER dataInvasive tumorsHigh-grade invasive cancerLow-grade DCISNon-calcified DCISProportion of DCISPure invasive tumorsInvasive breast cancerPresence of necrosisGrade of DCISLow-grade cancerPresence of calcificationLow gradeDCIS extentMicropapillary histologyGrade DCISPure DCISRetrospective reviewBreast cancerDCISBreast screeningCancer decreases
2009
Association between HER2/neu overexpression and calcifications in breast cancer
Christy C, Rishi M, Schwartz J, Grube B, Bossuyt V, Philpotts L, DiGiovanna M, Tavassoli F, Lannin D. Association between HER2/neu overexpression and calcifications in breast cancer. Journal Of Clinical Oncology 2009, 27: 579-579. DOI: 10.1200/jco.2009.27.15_suppl.579.Peer-Reviewed Original ResearchNeu overexpressionBreast cancerReceptor negativityInvasive tumorsNeu positivityMammographic calcificationsHER2/neu overexpressionHormone receptor negativityProgesterone receptor negativityHormone receptor statusInvasive breast cancerMultivariate logistic regressionPresence of necrosisImportant tumor markerHistologic calcificationLymphovascular invasionNodal statusReceptor statusRetrospective reviewTumor sizeInvasive cancerHistologic characteristicsTumor gradeClinical usefulnessHistologic examination
2008
Adenoma-infiltrating Lymphocytes (AILs) are a Potential Marker of Hereditary Nonpolyposis Colorectal Cancer
Polydorides A, Mukherjee B, Gruber S, McKenna B, Appelman H, Greenson J. Adenoma-infiltrating Lymphocytes (AILs) are a Potential Marker of Hereditary Nonpolyposis Colorectal Cancer. The American Journal Of Surgical Pathology 2008, 32: 1661-1666. PMID: 18753941, PMCID: PMC3500084, DOI: 10.1097/pas.0b013e31816ffa80.Peer-Reviewed Original ResearchConceptsHereditary nonpolyposis colorectal cancer syndromeColorectal adenomasControl adenomasHereditary nonpolyposis colorectal cancer patientsColorectal cancer syndromePresence of high-grade dysplasiaTumor-infiltrating lymphocytesHigh-grade dysplasiaPresence of necrosisNumbers of mitotic figuresColorectal cancer patientsHost immune responseVillous componentCancer syndromesLack of dirty necrosisSerrated architectureMicrosatellite-unstable colorectal cancersPatient ageGeneral populationPoor differentiationDirty necrosisInexpensive markerHistological featuresColorectal cancerAdenomas
2000
A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome
Camp R, Rimm E, Rimm D. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000, 88: 108-113. PMID: 10618612, DOI: 10.1002/(sici)1097-0142(20000101)88:1<108::aid-cncr15>3.0.co;2-b.Peer-Reviewed Original ResearchConceptsTumor-free lymph nodesLymph node negative breast carcinomaNode-negative breast carcinomaNegative breast carcinomaFree lymph nodesLymph nodesBreast carcinomaPrognostic valueTumor-free axillary lymph nodesTumor-negative lymph nodesDetectable lymph nodesNegative lymph nodesAxillary lymph nodesLymph node hyperplasiaLymph node metastasisReliable prognostic indicatorPresence of necrosisAxillary resectionLymphovascular invasionMetastatic diseasePatient ageIndependent predictorsLymphocytic infiltrateNode metastasisAggressive disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply